REVIEW ARTICLE

Signal co-operation between integrins and other receptor systems

Charles H. STREULI¹ and Nasreen AKHTAR

Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, U.K.

The multicellular nature of metazoans means that all cellular processes need to be tuned by adhesive interactions between cells and their local microenvironment. The spatial organization of cells within tissues requires sophisticated networks of extracellular signals to control their survival and proliferation, movements and positioning, and differentiated function. These cellular characteristics are mediated by multiple inputs from adhesion systems in combination with soluble and developmental signals. In the present review we explore how one class of adhesion receptor, the integrins, co-operate with other types of receptor to control diverse aspects of cell fate. In particular

we discuss: (i) how $\beta 3$ and $\beta 1$ integrins work together with growth factors to control angiogenesis; (ii) how $\alpha 6 \beta 4$ integrin co-operates with receptor tyrosine kinases in normal epithelial function and cancer; (iii) the interplay between $\beta 1$ integrins and EGF (epidermal growth factor) receptor; (iv) signal integration connecting integrins and cytokine receptors for interleukins, prolactin and interferons; and (v) how integrins and syndecans co-operate in cell migration.

Key words: adhesion complex, adhesome, cytokine receptor, growth factor receptor, integrin, integrin signalling, syndecan.

INTRODUCTION

The formation of complex organs, the organization of cells within them, and the expression of tissue-specific genes require a combination of spatial instructions from the ECM (extracellular matrix) and intercellular adhesions, together with temporal signals from soluble factors such as GFs (growth factors), hormones and cytokines. The precise integration of the resulting intracellular signalling networks drives the principal cellular processes of suppression of apoptosis, cell cycle, migration and differentiation, which are all key to the morphogenesis and function of tissues (Figure 1). In the present review we provide an overview of some of the pathways that are activated co-ordinately by the integrin class of cell-matrix receptor and other receptor systems, and discuss the current knowledge of the mechanisms by which signal co-operation regulates cell fate and development in both normal tissue homeostasis and disease.

Cell adhesions occur through a wide variety of cell-surface receptor systems, and one of the major classes are termed integrins. They are composed of α - and β -dimers, which combine to form 24 $\alpha \beta$ heterodimeric receptors, each with their own ligand specificities [1]. Integrins contain the binding sites for physical attachment of cells to the ECM, and they connect to various components of the actin cytoskeleton and signalling enzymes via their intracellular domains [2–4] (Figure 2). This provides the architectural framework for cells to organize their shape, respond appropriately to their microenvironment, and to establish stem-cell niches [5–7]. Integrins themselves can direct the type of ECM deposited and how it is organized on the extracellular face of cells. In turn, the spatial orientation of the ECM provides the

context for cells to migrate directionally and to proliferate in specific orientations, contributing to the highly ordered patterning of multicellular tissues [8,9]. Some integrins are also cell–cell adhesion receptors, although this aspect of their function will not be discussed in the present review.

Central to the process of cell adhesion is integrin clustering. This occurs through integrin aggregation co-ordinated by: (i) close proximity or periodicity of ligand-binding sites within the cross-linked matrix of ECM molecules; (ii) lateral associations of integrins, possibly as repeating trimers, or via tetraspanins or lipid islands within the plane of the plasma membrane [10–12]; and (iii) interactions between integrin cytodomains via structural dimers (e.g. talin) [13]. Integrin clusters form a stable membrane platform with a high avidity for the ECM on the outside of the cell and, on the inside, they have multiple binding sites for adaptors and enzymes that become compartmentalized into plasma membrane-associated complexes. An adhesion complex is a multi-component complex that is frequently big enough to be seen by fluorescence microscopy and can be considered to be an organelle within the plasma membrane. There are a variety of types of integrin adhesion complexes, including focal complexes, focal adhesions, fibrillar adhesions, podosomes etc., and in the present review we refer to them collectively as adhesomes, as described in [2]. Adhesome is a useful word to call a broad collection of adhesion structures, based on ‘adhesion complex’ and the Greek ‘soma’, meaning body. Intracellularly, adhesomes assemble the cytoskeleton, signalling enzymes, and possibly other membrane microdomains such as lipid rafts [14].

The kind of $\alpha \beta$ integrin heterodimer, and the composition, density and rigidity of ECM molecules, as well as the cell type,

Abbreviations used: Ang-1, angiopoietin-1; Cdk, cyclin-dependent kinase; ECM, extracellular matrix; GF, growth factor; EGF, epidermal GF; EGFR, EGF receptor; ERK, extracellular-signal-regulated kinase; FAK, focal adhesion kinase; FGF, fibroblast GF; FN, fibronectin; GAG, glycosaminoglycan; GEF, guanine-nucleotide-exchange factor; HGF, hepatocyte GF; IFN, interferon; IGF-1, insulin-like GF-1; IL, interleukin; ILK, integrin-linked kinase; IRS, insulin receptor substrate; JAK, Janus kinase; JNK, c-Jun N-terminal kinase; LM, laminin; MAPK, mitogen-activated protein kinase; NF- κ B, nuclear factor κ B; PAK, p21-activated kinase; PDGFR, platelet-derived GF receptor; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PP2, protein phosphatase 2; PTP, protein tyrosine phosphatase; RTK, receptor tyrosine kinase; Shc, Src homology and collagen homology; SHP, Src homology 2 domain-containing protein tyrosine phosphatase; STAT, signal transducer and activator of transcription; TCTP, T-cell PTP; TGF- β , transforming GF- β ; VEGF, vascular endothelial GF; VEGFR, VEGF receptor; VN, vitronectin.

¹ To whom correspondence should be addressed (email cstreuli@manchester.ac.uk).

Figure 1 Concepts of integrin function

(a and b) Integrins are essential for matrix deposition and therefore they organize the microenvironment surrounding cells (a) and control cell-fate decisions (b). (c) Key aspects of cell fate controlled by integrins. (d) Disruption of the ECM–integrin–intracellular link leads to several of the important diseases of humankind.

specifies the profile of recruited proteins [15]. In turn, the type of adaptors and enzymes within adhesomes determines distal signalling events and thereby cell-fate decisions (Figure 3). Some of these are classical signalling enzymes, for example Src directly binds the β integrin tail and activated JNK (c-Jun N-terminal kinase) is detected in integrin adhesions [16,17]. Numerous signal-transduction pathways are triggered downstream of integrin engagement, including those involving Rho family GTPases, protein kinases, lipid kinases and phosphatases [18–20].

Some signalling enzymes are regulated by both integrins and GF/cytokine receptors, providing key nodal points at which the two systems can interplay [21]. Although the different receptor types can be activated separately by their own ligands, ECM adhesion can trigger GF receptors and vice versa. Moreover, in many cases engagement of both adhesion and GF receptors is required for an optimal output of sustained synergistic signalling. Integrins are relatively stable and the ECM is not diffusible, which means that integrins are microenvironmental sensors providing positional information over a sustained period of time. Depending on the location of cells, integrins determine whether a cell is able to respond to the more temporal signals provided by diffusible factors. Integrins are therefore positional checkpoints for cell-fate decisions induced by GFs or cytokines [22] (Figure 4).

Since the balance of normal tissue homeostasis requires integration of spatial ECM signals with other receptor systems, dissecting the molecular mechanisms governing these processes is key to understanding many diseases. (In experimental terms, the interaction of cells with two-dimensional substrates have major differences in biological response to the more natural three-dimensional environments that cells are embedded within *in vivo*, which is important to bear in mind when considering how integrins work in tissues [23–25]. While two-dimensional cultures are unlikely to reveal how adhesion signals control biological endpoints in tissues, they are frequently used to

Figure 2 Integrin connections

(a) Integrins are α - β heterodimers that bind ECM proteins of stroma or basement membrane on the outside of the cells. (b) On the inside of cells, integrin clustering induces the formation of multi-protein aggregates called adhesion complexes, or sometimes known as adhesomes. Some of the many core adhesome proteins are shown. vinc, vinculin; Pax, paxillin; Cas, p130Cas. A fuller view of the proteins within the adhesome can be seen in [2], and some of the more recently identified components are discussed in [3]. (c) A fluorescence image showing integrin adhesions (red), the actin cytoskeleton (green) and nuclei (blue).

determine the initial signals that are engaged downstream of adhesomes.) Loss of connections between signalling networks contribute widely to diseases such as neoplasia. For example, one hallmark of cancers is ‘self-sufficiency in growth signals’, where certain GF receptors are no longer restrained by environmental cues so that their activation kinetics are extended, or they become otherwise deregulated [26]. Consequently, cancer cells can become independent of integrins, and thereby survive, proliferate or migrate within inappropriate ECM [27]. Conversely, some neoplastic cells take advantage of adhesion signals and up-regulate integrins at various stages of tumour progression, e.g. $\beta 6$ integrins are abnormally expressed in a wide range of carcinomas and activate TGF- β (transforming GF- β) [28], whereas $\alpha 6 \beta 4$ integrin, in some metastatic carcinomas, switches from a strong adhesion receptor to a signalling receptor that combines with RTKs (receptor tyrosine kinases) to enhance downstream signals and directional migration [29].

SIGNAL INTEGRATION BETWEEN INTEGRIN AND GF RECEPTORS

Integrins are both sensors and machines. They sense the ECM content of the environment and communicate this information

Figure 3 Integrin assemblies regulate cell phenotype

(a) Integrin assemblies between the ECM and adhesion complex organize the cytoskeleton, which controls cell shape, polarity and migration. (b) Recruitment of adaptors and signalling enzymes to integrin adhesions controls proliferation, apoptosis and differentiation.

Figure 4 Integrin adhesion is a positional checkpoint for cell-fate decisions

(a) Soluble factors control development temporally, but their signals are only interpreted by the cell in the context of integrin adhesion complexes (b) and cell-cell interactions (c), which together provide microenvironmental checkpoints for cell fate (i.e. phenotype) decisions (d).

to the inside of the cell directly by receptor activation through 'outside-in' signalling. This leads ultimately to decisions on cell fate, which has been documented in some cases at the level of cellular gene expression profiles; in a recent example, $\alpha 6 \beta 4$ integrin controlled the expression of genes involved in motility and invasion [30]. At the same time integrins are the core component of multi-protein machines that facilitate the attachment of cells to the

Figure 5 Integrins are sensors and machines

(a) The mechanical links between integrins and the ECM can be enhanced by *trans*-signalling from GFs or other ligands. (b) Integrins sense the ECM, which affects ligand activation of GF receptors. In the ECM (i), the rheostat activity of adhesion complexes is low, only permitting ligand-receptor interactions to deliver weak or transient signals. (ii) The ECM provides stronger more sustained signals.

ECM and/or migration through (or across) it, and in this respect ligand-binding activity is controlled via 'inside-out' signalling.

GF regulation of integrins

GFs can influence integrin function. One mechanism is by altering the expression of integrin α/β pairs or adhesome components. For example FGF-2 (fibroblast GF-2) increases $\alpha 5 \beta 1$ integrin expression in endothelial cells, whereas TGF- $\beta 1$ elevates $\beta 1$ and $\beta 5$ integrin levels and induces *de novo* synthesis of $\alpha v \beta 6$ in keratinocytes [31,32]. How integrins are regulated has been discussed recently in the context of development and integrin trafficking, and a newly discovered mechanism for controlling integrin levels is through microRNAs, where the let-7a microRNA directly affects $\beta 3$ integrin expression [33–35]. Moreover, tetraspanins can control integrin function in several ways, for example CD151 regulates $\alpha 3$ and $\alpha 6$ integrins through glycosylation and trafficking [36–38].

Soluble factors also indirectly activate the ability of integrins to bind to the ECM via conformational molecular changes in the integrin molecules [39,40] (Figure 5a). In this context, the most important role of integrin activation is in dynamic cellular responses, such as in immune cell function, tissue repair and embryonic development. For example, immune cells, changing from circulating to migrating cells, undergo chemokine-regulated integrin activation [41]; platelet integrins become activated in the clotting cascade [42]; and keratinocyte integrin usage and function switches during wound repair [43].

The topic of inside-out signalling has been discussed widely [44]; however, it is not known whether or not regulated inside-out signalling occurs in the normal homeostasis of static cells within tissues. Most normal epithelial, mesenchymal or neuronal cells maintain their spatial organization *in vivo*, and it remains

to be established whether the ability of integrins to bind ECM is regulated or constitutive.

Integrin regulation of GF receptors

GFs direct cell-fate decisions during development. However, the signalling responses of GF receptors (i.e. RTKs) are intricately controlled by adhesion to the ECM, where synergy leads to an optimal response. Integrin interception of GF signalling can occur at the receptor level, where integrins may influence expression, localization or post-translational modification of RTKs, or levels of GFs themselves. Moreover, in some cases integrins directly regulate GF activation prior to receptor binding, for example the αv integrins control TGF- β signalling via latency-associated peptide [45]. Integrins and RTKs can also interconnect via shared downstream signalling molecules [46].

One mechanism for activating GF receptors is through integrin clustering, in which integrin–RTK complexes can trigger RTK activity in the absence of the GF [47,48]. Several RTKs can be stimulated simply by adhesion to the ECM, including PDGFR (platelet-derived GF receptor), EGFR [EGF (epidermal GF) receptor; also known as ErbB1], bFGFR (basic FGF receptor), VEGFR [VEGF (vascular endothelial GF) receptor] and c-Met [HGF (hepatocyte GF) receptor] [21]. Such interactions are generally specific to the integrin subunit. For example, the receptors for insulin, IGF-1 (insulin-like GF-1) and VEGF are found in immune complexes with $\alpha v\beta 3$, whereas ErbB2 and c-Met receptors specifically associate with $\alpha 6\beta 4$ integrin. EGFR is more promiscuous, interacting with $\beta 1$, $\beta 3$ and $\beta 4$ integrins. Many of these receptor–receptor connections are likely to be indirect within an adhesome, and it will be interesting to determine whether they can be visualized either by direct imaging or by FRET (fluorescence resonance energy transfer;), which has been successful for viewing integrin α – β subunit interactions [49].

The clustering of specific integrins within lipid microdomains can also influence RTK activation by their enrichment into those areas, thereby facilitating RTK activation by *trans*-phosphorylation [50]. Examples of integrin–RTK interactions at lipid rafts include $\alpha 6\beta 4$ with EGFR in keratinocytes and $\alpha 6\beta 1$ with PDGFR in oligodendrocytes [51,52].

Although adhesion directly activates GF receptor signalling in some experimental models, our view is that under homeostatic conditions *in vivo*, the interactions between adhesion and GF receptors have a regulatory role. Thus the activated integrin behaves as a rheostat to control RTK signalling output, by modulating its intensity and duration (Figure 5b). This means that the ECM environment of the cell determines how the cell responds to soluble factors. For example insulin and IGF receptors only activate downstream signals efficiently in mammary epithelial cells on a basement membrane, but not stromal, ECM, correlating with location-dependent survival within tissues [53–55]. The corollary is that altered expression or composition of integrin α and β subunits significantly changes GF signalling responses. This causes profound cell-behavioural changes in diseases where the ECM is altered, for example in fibrosis and cancer, or if there are mutations or epigenetic changes in integrin levels such as in blistering diseases and cancer.

Below are some examples of integrin subunit-specific partnerships with RTKs in modulating cellular responses and developmental processes.

$\beta 3$ and $\beta 1$ integrins collaborate with RTKs to control angiogenesis

The development of new capillaries from pre-existing blood vessels (i.e. angiogenesis) occurs in embryonic development,

reproduction, tissue regeneration and in pathological conditions such as cancer, rheumatoid arthritis and diabetic microvascular disease. Vessel morphogenesis requires a co-ordinated regulation of cell proliferation, migration and differentiation into tubes, providing an elegant example of a developmental co-operation between GFs and integrin–ECM adhesion [56].

The role of $\alpha v\beta 3$ integrin

Both GFs and integrins are central to angiogenesis. For example, VEGF-A regulates angiogenesis through the RTK, VEGFR-2 [KDR (kinase insert domain-containing receptor) or Flk-1], which is specifically expressed on endothelial cells. Mice lacking VEGFR-2 show an impaired vasculature and early embryonic lethality [57]. Tumour development and ischaemic diseases often display increased VEGF production, and inhibiting the ligand or its receptors reduces tumour growth in multiple models [58]. Similarly, integrins also regulate angiogenesis; for example, endothelial $\alpha v\beta 3$ is highly up-regulated at active angiogenic sites associated with tissue regeneration, inflammation and tumours, and blocking-antibodies or small-molecule inhibitors against $\alpha v\beta 3$ potentially inhibit tumour angiogenesis *in vivo*, with the latest therapies being delivered via nanoparticles [59,60].

There are several lines of evidence indicating that a direct interplay between these two receptor types, i.e. $\alpha v\beta 3$ integrin and VEGFR-2 occurs at the biochemical level. (i) Attachment of HUVECs (human umbilical-vein endothelial cells) to $\alpha v\beta 3$ -specific ECM ligands [VN (vitronectin), fibrinogen] increases VEGF-A-induced mitogenesis, and a $\beta 3$ integrin-blocking antibody prevents tyrosine phosphorylation of VEGFR-2 by its cognate ligand [61]. (ii) The $\beta 3$ (but not $\beta 1$ or $\beta 5$) integrin forms a physical complex with VEGFR-2 in co-immunoprecipitates, an interaction that requires tyrosine phosphorylation of the $\beta 3$ integrin cytoplasmic domain [62]. (iii) $\alpha v\beta 3$ and VEGFR-2 also co-regulate angiogenesis via activation of shared downstream molecules; for example, c-Src complexes with both VEGFR-2 and $\alpha v\beta 3$, it directly phosphorylates the cytosolic tail of $\beta 3$ integrin in response to VEGF, Src regulates the activation and ligand-binding of $\beta 3$, and it is required for tube formation [63]. c-Src also modulates VEGF-induced vascular permeability and blood vessel development in animal models, and VEGF promotes c-Src-mediated FAK (focal-adhesion kinase) recruitment to a related integrin, $\alpha v\beta 5$ [64,65]. (iv) Another adhesion-complex protein, ILK (integrin-linked kinase), which binds cytoplasmic domains of both $\beta 1$ and $\beta 3$ integrin, is also implicated in VEGF-induced capillary formation [66]. Since PKB (protein kinase B)/Akt activation by VEGF is important for angiogenesis, and ILK contributes to Akt activation via rictor [rapamycin-insensitive companion of mTOR (mammalian target of rapamycin)], there may also be downstream co-operation through this signal integrator [66,67].

Interestingly, subunit-specific deletion experiments question the role of $\alpha v\beta 3$ for angiogenesis *in vivo* [68]. Mice lacking $\beta 3$ and $\beta 5$ integrins display normal developmental angiogenesis and are viable, suggesting that these subunits may not have a role in embryonic development, although there are some cardiovascular defects in adult male mice lacking $\beta 3$ integrin [69]. Indeed, $\alpha v\beta 3$ integrin has anti-angiogenic properties in the case of pathogenic vascular development, because mice lacking $\beta 3$ and $\beta 5$ integrins not only develop tumours but actually display enhanced angiogenesis and increased tumour growth, mediated by elevated VEGFR-2 signalling [70]. These findings raise questions as to precisely how $\alpha v\beta 3$ integrin regulates both developmental and pathological angiogenesis, and the importance of the $\beta 3$ subunit in these processes. One possibility is that the αv integrin subunit is more critical (it is promiscuous for

Figure 6 $\alpha 5 \beta 1$ integrin co-operates with GFs

(a) A soluble VEGFR directly binds integrins. The signalling consequences of this interaction are not known. (b) $\alpha 5 \beta 1$ integrin is a rheostat for Ang-1 signalling through Tie2. (c) Integrins collaborate with RTKs via caveolin-1 and lipid rafts, recruiting a variety of signalling enzymes that contribute to cell-cycle activation.

β integrins), because 30% of mice null for this subunit die at birth through vascular defects, although angiogenesis at early stages of embryonic development appears normal [71]. Nonetheless, the interdependency between $\alpha v \beta 3$ and VEGFR-2 still exists, and it is bi-directional since VEGF-A induces $\alpha v \beta 3$ expression while deletion of the $\beta 3$ subunit elevates VEGFR-2 [70]. Maybe $\beta 3$ integrins have more subtle roles than have previously been recognized, with both pro- and anti-angiogenic effects in order to prevent unrestrained vasculogenesis during developmental angiogenesis. An interesting concept is that the αv integrins have evolved as a second tier of adhesion receptors that are mainly utilized for repair processes such as wound healing and inflammation, while the $\beta 1$ integrins have more fundamental roles in embryogenesis and tissue homeostasis.

The role of $\alpha 5 \beta 1$ integrin

$\alpha 5 \beta 1$ integrin and its ligand, FN (fibronectin), have essential roles in vascular development, co-operating with GFs in three ways [72]. (i) A soluble form of VEGFR-1 that is deposited into the ECM, binds directly to $\alpha 5 \beta 1$ integrin and promotes endothelial cell adhesion and migration, through a specific peptide sequence within its Ig-like domain II [73]. Although there is no lateral interaction between $\alpha 5 \beta 1$ and transmembrane VEGFR-1 (Flt-1), the soluble VEGFR-1 may contribute to vessel development and angiogenesis via integrins (Figure 6a). (ii) $\alpha 5 \beta 1$ forms a stable interaction with a separate class of angiogenic RTK, Tie2, which is a receptor for the angiopoietin, Ang-1 (angiopoietin-1) [74]. $\alpha 5 \beta 1$ integrin is required for Ang-1-mediated blood vessel formation *in vivo*, and the co-receptor complex is enhanced when cells adhere to FN, correlating with increased endothelial cell migration. The association of integrin with Tie2 therefore

acts like a rheostat to amplify both the strength and duration of angiogenic signals (Figure 6b). Mechanistically, it may be that optimal receptor output occurs when integrins recruit FAK and the RTK binds the PI3K (phosphoinositide 3-kinase) p85 subunit, providing synergy for efficient downstream Akt signals. (iii) $\alpha 5 \beta 1$ integrin also co-operates with other RTKs, such as the receptors for bFGF, insulin and EGF, to activate cyclin D1 and thereby drive endothelial cell-cycle progression (Figure 6c) [75]. The $\alpha 5 \beta 1$ -RTK synergy occurs through a concerted activation of PI3K (probably via FAK) and Shc (Src homology and collagen homology), with consequent recruitment of the GEF (guanine-nucleotide-exchange factor), SOS (Son of sevenless), then activation of Rac1 and (unknown) downstream signals to cyclins. The link between receptors may depend on integrins binding to a phosphorylated form of a membrane adaptor, caveolin-1, which recruits Rac to lipid rafts [76]. Caveolin also binds Fyn and thereby Shc, and caveolin-1 can be visualized in focal adhesions, so representing an integrin-to-GF receptor node for activating multiple signalling enzymes [77].

The role of other $\beta 1$ integrins

Other $\beta 1$ integrins also contribute to angiogenesis, with the laminin receptor $\alpha 3 \beta 1$ being negatively involved in tumour angiogenesis, and the collagen receptor $\alpha 1 \beta 1$ restraining the activity of VEGFR-2 [56,78]. Interestingly, in the latter case, the suppression of signalling on collagen is via recruitment of the phosphatase, SHP-2 (Src homology 2 domain-containing protein tyrosine phosphatase 2), to VEGFR-2, which resembles the mechanism of inhibition of prolactin receptor signalling in mammary cells on the same ECM (see below) [79]. Finally, the $\alpha 6 \beta 1$ laminin receptor may have a key role in switching the proliferation phase of angiogenesis to a morphological one where the cells form tubes, because it does not permit RTK-dependent cell-cycle signals in the way that $\alpha 5 \beta 1$ does, but rather promotes differentiation [75].

Summary

The formation of blood vessels is a relatively simple programme in development involving the proliferation, migration and cellular reorganization of endothelial cells (and pericytes). Although RTK ligands provide a direct activation mechanism for angiogenesis, co-ordinating these three different types of cellular responses to create hollow tubes within a complex ECM environment requires numerous positive and negative signals. Integrins are central in this process, controlling and co-ordinating the outcome of extracellular GF signals.

Major gaps in knowledge

Major gaps in knowledge include: (i) the molecular details of precisely how the two receptor systems interact, both within the plane of the membrane and at the level of signal integration; (ii) the details of how different α integrin subunits direct the phenotypic endpoints, i.e. proliferation compared with tubular morphogenesis; and (iii) differences of integrin-RTK interactions in normal and pathological angiogenesis.

$\alpha 6 \beta 4$ integrin co-operates with RTKs in normal epithelial function

Hemidesmosome architecture

The LM (laminin) receptor $\alpha 6 \beta 4$ is the classic core component of hemidesmosomes [80]. In normal epithelial cells, especially those prone to mechanical shear stresses such as epidermal keratinocytes, $\alpha 6 \beta 4$ performs adhesive functions by interacting

Figure 7 The dynamics of $\alpha 6\beta 4$ integrin

(a) Schematic diagram of hemidesmosomal components which provide a continuous mechanical link between the ECM and intermediate filament network. Lateral clusters of these units are the building blocks of hemidesmosomes, which are mechanical adhesive devices for cells. CVII, collagen VII; IF, intermediate filaments. (b) RTK signalling causes the phosphorylation of serine residues on $\beta 4$ integrin, leading to dissociation of plectin and disassembly of hemidesmosomes. $\alpha 6\beta 4$ integrin may be converted into a migration machine via tyrosine phosphorylation. S-P, phosphorylated serine; Y-P, phosphorylated tyrosine.

with LM-5 (laminin332) in the basement membrane, which binds collagen VII then collagen I within the dermis. On the inside of the cell it binds to plectin which directly links to the keratin cytoskeleton, and together with BP180 and BP230, this multiprotein complex forms massive adhesion plaques that stabilize tissue architecture (Figure 7a) [81]. The importance of $\alpha 6\beta 4$ is demonstrated by skin defects in humans with $\beta 4$ integrin mutations, and epidermal blistering and postnatal death in mice lacking the $\beta 4$ cytoplasmic tail [82,83].

However, the enormous strength of these adhesions means that they need to be undone at certain times. In order for epidermal cells to undergo cytokinesis, enter the supra-basal cell layer during stratification, or to migrate laterally in a wound-healing response, hemidesmosomes become destabilized, and this occurs through RTK signalling to $\alpha 6\beta 4$ integrin.

The $\beta 4$ integrin subunit is unique by virtue of a long cytoplasmic tail. This region provides a variety of binding sites for cytoskeletal and signalling proteins, making it distinct from other integrins. The N-terminal half of this segment contains the binding domain for plectin, whereas the distal half has multiple serine and tyrosine phosphorylation sites. Targeted deletion of the phosphorylation domain (C-terminal to the plectin-binding region) has no effect on the formation and stability of hemidesmosomes, in contrast with mice lacking the entire $\beta 4$ cytoplasmic tail, indicating that phosphorylation sites are not required for epidermal adhesion [84].

RTKs alter the dynamics of $\alpha 6\beta 4$ integrin

Dynamic processes such as wound healing are necessarily accompanied by destabilization of cellular adhesions. Under these conditions, $\beta 4$ integrin redistributes from hemidesmosomes to actin-based structures at leading edges of cells, where it actively promotes migration and proliferation in conjunction with GFs

secreted at the wound [85]. The disassembly of hemidesmosomes is mediated by GFs, e.g. EGF, which induces the phosphorylation of three highly conserved serine residues on $\beta 4$ integrin via PKC α (protein kinase C α), and possibly PKA (protein kinase A) [86]. These modifications destabilize the interaction between plectin and $\beta 4$ and thereby break down adhesion complexes (Figure 7b). The phosphorylation region of $\beta 4$ integrin is required for keratinocyte migration and signalling because its deletion suppresses wound closure (and also inhibits proliferation and enhances apoptosis in cultured cells) [84].

One possible link between $\beta 4$ and migration lies in the association of non-hemidesmosomal $\alpha 6\beta 4$ integrin with a fraction of EGFR. This interaction occurs within lipid rafts and leads to the activation of Fyn, which can phosphorylate tyrosine residues in the $\beta 4$ integrin tail, causing recruitment of Shc and activation of downstream enzymes [51]. One of these is Rac, which is downstream of both $\beta 4$ integrin and EGFR, and has a central role in directional cell migration [87,88].

Re-epithelialization of wounds is also accompanied by cytokines such as macrophage-stimulating protein, which contributes to hemidesmosome disassembly via its receptor Ron [89]. Ron activation results in serine phosphorylation of $\beta 4$ integrin, which presumably has a similar effect to EGFR in displacing plectin. However, in addition, 14-3-3 proteins bind the modified serine residues of $\beta 4$ leading to the formation of a $\beta 4$ -14-3-3-Ron complex, which relocates to lamellipodia and causes accelerated wound healing *in vivo*. This cross-talk is reciprocal, since integrins trigger Ron phosphorylation and kinase activity, most likely through Src/FAK signalling [90].

Summary

Although $\alpha 6\beta 4$ integrin is conventionally thought of as being a receptor for stable adhesions, its role is much more

sophisticated. Thus, in normal wound repair, multiple RTKs switch the function of this core hemidesmosomal component from a mechanical adhesive assembly into a migration and signalling ECM receptor (Figure 7). Interestingly, it seems that serine phosphorylation destabilizes the hemidesmosomes, whereas tyrosine phosphorylation promotes migration.

$\alpha 6 \beta 4$ integrin co-operates with RTKs in epithelial cancer

Although the above provides an elegant mechanism for creating stable epithelial tissues, with the option of dynamic repair when the situation arises, it is susceptible to abuse. $\beta 4$ integrin has a central role in the progression of several tumour types, where it combines with mutated or amplified RTKs, including EGFR, ErbB2 and c-Met [91–93]. These RTKs inappropriately phosphorylate tyrosine residues within the distal half of the $\beta 4$ cytoplasmic tail, thereby preventing the assembly of hemidesmosomes and promoting invasion instead [43].

$\alpha 6 \beta 4$ -RTK co-operation in migration and survival

A link between the $\alpha 6 \beta 4$ and ErbB2 receptors was reported initially in breast carcinoma cell lines where their association enhanced migration [94]. The invasive effects of this receptor pairing are mediated in part by the PI3K/Akt pathway, which activates Rac1. ErbB3, which is a strong activator of PI3K/Akt, might be involved as well, since $\alpha 6 \beta 4$ integrin elevates the translation of ErbB2 and ErbB3, and so potentially transactivates both EGFR/ErbB2 and ErbB2/ErbB3 [95,96]. The mechanism of receptor synergy between $\alpha 6 \beta 4$ and RTKs in cancer cells has not been fully resolved, but their physical association may promote tyrosine phosphorylation on the $\beta 4$ tail: in addition to altering hemidesmosome stability, this also provides SH2-binding sites for several signalling proteins including the p85 subunit of PI3K. As mentioned above, this may occur via Fyn in the context of EGFR activation. Ligation of $\alpha 6 \beta 4$ promotes an interaction with the adaptor protein, IRS (insulin receptor substrate), which itself binds and activates PI3K [97].

$\alpha 6 \beta 4$ integrin is also implicated in cancer-cell invasion mediated by another RTK, c-Met (the receptor for HGF, originally known as scatter factor). A constitutively active form of Met, which is present in some cancer cell lines, physically associates with $\alpha 6 \beta 4$ integrin. In overexpression studies, Met induces $\beta 4$ integrin tyrosine phosphorylation and recruitment of Shc and hence PI3K, promotes transformation and tumorigenesis of cell lines, and both receptors are required for HGF to cause cell invasion [98]. However, it is not certain whether this integrin–RTK interaction really occurs *in vivo* because other studies indicate that Met and $\alpha 6 \beta 4$ have separate and independent roles in cancer-cell invasion, and the $\beta 4$ intracellular domain by itself can not enhance HGF signalling [99,100].

$\alpha 6 \beta 4$ also mediates anchorage-independent survival of breast cancer cells. This occurs through Akt, and via a mechanism involving Rac, PAK (p21-activated kinase) and NF- κ B (nuclear factor κ B) [101,102]. Confirmation of the role for $\beta 4$ integrin in cancer-cell survival comes from shRNA (small hairpin RNA) studies, where $\beta 4$ knockdown promotes apoptosis [103].

$\alpha 6 \beta 4$ -RTK co-operation in tumorigenesis

Whether any of these are *bona fide* mechanisms in human tumours is not yet known. In the MMTV-Neu mouse model for breast cancer (which carries an activated form of ErbB2), targeted deletion of the $\beta 4$ cytoplasmic domain suppresses tumour onset and invasive growth, arguing for a functional association. In primary cells isolated from these tumours, $\beta 4$ integrin complexes

with ErbB2 and enhances signalling by activating STAT3 (signal transducer and activator of transcription 3), nuclear translocation of JNK and phosphorylation of c-Jun [104].

However, contrasting with this, in one study of human breast cancer, $\beta 4$ integrin expression was strongly associated with ‘basal’ tumours, but not with ErbB2, and in another study there was no association between $\beta 4$ and ErbB2. Instead, all of the tumours with elevated ErbB3 also had a higher level of $\beta 4$ integrin [29,105]. Thus while there is compelling evidence that the $\beta 4$ integrin has an important role in cancer progression, its mechanism of involvement is not certain.

Major gaps in knowledge

Major gaps in knowledge include whether or not $\alpha 6 \beta 4$ -RTK interactions actually occur during tumorigenesis *in vivo*, and if so which residues are phosphorylated and what the *trans*-phosphorylation mechanism might be. $\beta 4$ integrin may be a good new therapeutic target for aggressive cancers, but chiselling out the mechanism of its involvement will be necessary to develop strategies which prevent tumour invasion and at the same time do not perturb either normal hemidesmosomes or wound repair.

$\beta 1$ integrins, RTKs and the cell cycle

One further example of integrin–RTK cross-talk is worth mentioning because it provides some additional clues about the mechanisms of synergy. $\beta 1$ integrins co-operate with EGFR (ErbB1) in several cell types in the context of classical signalling output via the ERK (extracellular-signal-regulated kinase) and Akt pathways, and this has important implications for regulation of diverse aspects of cell fate, including proliferation [106].

All adherent cells require ECM adhesion to progress through the cell cycle. Thus RTK activation is not sufficient for proliferation and integrin signalling is needed as well. It has been established for some time that integrin adhesion is required in fibroblasts for the activation of MEK [MAPK (mitogen-activated protein kinase)/ERK kinase] downstream of Raf, translocation of ERK into the nucleus and phosphorylation of Elk-1 [ETS (E twenty-six)-like kinase 1], transcription of an EGF-responsive gene *Erg-1*, degradation of p27 via the ubiquitin ligase Skp-2 (S-phase kinase-associated protein 2), expression of cyclin D1 and progression through G₁/S-phase [107–111] (Figure 8a).

The mechanism for this requirement of integrins involves both a direct cross-talk with RTKs such as EGFR, and RTK-independent signalling from adhesomes. However, integrins are not able to activate RTK sufficiently to trigger the cell cycle without GFs. Thus the cell cycle progresses through a combination of GF–RTK, integrin–RTK and direct-integrin signals (Figure 8b). These distinct modes of signal integration by extracellular ligands may be necessary to ensure that both the early and late stages of the cycle are accomplished in order to pass through the restriction point and enter S-phase [112].

$\beta 1$ integrin activation of EGFR

In primary fibroblasts and ECV304 endothelial cells, integrin-mediated adhesion results in rapid tyrosine phosphorylation and kinase activation of the EGFR [48,113]. This occurs in the absence of any RTK ligands, and in cells that have moderate levels of EGFR ($> 3 \times 10^4$ receptors/cell), adhesion induces ShcA phosphorylation and ERK kinase activity via the EGFR. This is a direct activation mechanism since a fraction of EGFR associates with $\beta 1$ integrins in a complex with Src and p130Cas, and both the $\beta 1$ integrin cytoplasmic domain and Src/Cas are required

Figure 8 $\beta 1$ integrins and cell-cycle control

(a) Integrins regulate many of the steps in the GF-to-cell cycle pathway. (b) The cell cycle requires separate signals from (i) GFs, (ii) integrins and (iii) integrin-RTK interactions. (c) One mechanism of integrin-RTK cross-talk is via direct association between the receptors and indirect phosphorylation of several tyrosine residues and thereby ERK activation, whereas EGF causes phosphorylation of a separate residue, Tyr¹¹⁴⁸. The outputs are different, but both are required for cell-cycle progression.

for EGFR phosphorylation. Moreover, integrin activation leads to phosphorylation of a distinct subset of tyrosine residues to EGF, leaving the major EGF-responsive Tyr¹¹⁴⁸ unphosphorylated. Thus integrins directly affect the tyrosine phosphorylation of RTKs, thereby influencing their signalling output and phenotypic endpoints (Figure 8c).

This model has been extended with the use of COS-7 and CV1 cells, and primary prostate epithelial cells and keratinocytes, to show that integrins cause EGFRs to recruit a variety of adaptors independently of EGF, which stimulate the ERK and Akt pathways, then cyclin D1 synthesis and Cdk4 (cyclin-dependent kinase 4) and Rb (retinoblastoma) phosphorylation [114]. Separate ligand-induced activation of the EGFR is required for p27 down-regulation, Cdk2 activation, Myc and cyclin A induction and cell-cycle progression (Figure 8c).

Integrin activation of PDGFR

The mechanism of integrin activation of RTKs also involves proteins identified for cross-talk with a different receptor, PDGFR β [115]. In MEFs (mouse embryonic fibroblasts), integrin adhesion to FN promotes the association of SHP-2 with PDGFR β , leading to a positive effect on signalling. SHP-2 dephosphorylates the tyrosine residue that would otherwise bind RasGAP, with the consequence that Ras and ERK activation are sustained and more cells enter the cell cycle. SHP-2 may also increase tyrosine phosphorylation on SIRP α (signal regulatory protein α), which further contributes to adhesion-mediated ERK activation [116]. Through these mechanisms, and most likely Src-family kinases as well, $\beta 1$ integrins alter the ability of RTKs to recruit adaptors, thereby changing their signalling output and phenotypic endpoints.

RTK-independent integrin signalling

In cell types with very low levels of EGFR (e.g. 3T3 fibroblasts) the adhesion-to-ERK signalling is autonomous of RTKs, and can be triggered directly through adhesion enzymes, e.g. FAK/Src and/or GEFs/Rac [48]. Indeed, Rac1 is a key mediator of integrin signals for proliferation, via PAK1, and its activity is directly dependent on signals induced through the $\beta 1$ integrin tail and integrin recruitment to membrane microdomains [117–119]. Further complexity is revealed through the use of $\beta 1$ integrin-rescued $\beta 1$ -null GD25 cells, where the Akt pathway is triggered by separate mechanisms downstream of integrins and EGFR [120–122]. $\beta 1$ integrin activates Akt through a novel mechanism that is independent of EGFR and FAK/Src, Abl or other Src-family kinases, but involves an unknown PP2 (protein phosphatase 2)-inhibitable enzyme. Moreover EGFR can separately cause the phosphorylation of Akt on Ser²⁷³/Thr³⁰⁸ and it uniquely triggers a Src-dependent Tyr³²⁶ phosphorylation.

Integrin suppression of EGFR

In addition to activating RTKs, integrins also have a role in suppressing their activity. An example of this involves the PTP (protein tyrosine phosphatase), TCPTP (T-cell PTP), which binds specifically to the collagen receptor $\alpha 1\beta 1$ integrin, but not other collagen-binding integrins, as well as to EGFR [123]. $\alpha 1\beta 1$ integrin adhesion activates the phosphatase activity of TCPTP and inhibits ligand-induced EGFR phosphorylation. Although TCPTP does not adversely affect EGF-induced ERK activation, it does prevent EGFR interactions with ShcA-Grb2, and therefore has quite specific effects [124]. A challenge will be to identify how this and other inhibitory PTPs are involved with integrin-RTK cross-talk, as this may be crucial to limit proliferation and promote morphogenesis, particularly in three-dimensional developmental situations. Moreover, defects in such interactions could promote tumorigenesis, and it is of interest to note that ShcA is essential for tumour formation in an ErbB2 model of breast cancer [125].

$\beta 1$ integrin-EGFR cross-talk in tumours

A different mechanism of functional interplay between $\beta 1$ integrin and EGFR may be important in some transformed breast epithelial cell lines, and be of relevance to tissue organization and possibly cancer progression. A normal breast line adapted to culture in the presence of EGF becomes tumorigenic after a few generations in the absence of EGF, due to the acquisition of an extra chromosome 7p harbouring the EGFR gene [126]. In comparison with the parental cells, which form hollow acini in three-dimensional culture, the tumorigenic cells form

disorganized cellular aggregates. This is caused by acquisition of *de novo* integrin–EGFR interactions, because function-blocking antibodies to either $\beta 1$ integrin or EGFR: (i) inhibit EGFR-to-MAPK signalling, (ii) revert the disorganized morphology to normal acinar appearance with hollow lumens, and (iii) reduce tumour incidence *in vivo* [127]. There is a related restoration of ‘normal’ three-dimensional architecture of some breast cancer lines (Hs578T and MB-MDA-231) by anti- $\beta 1$ integrin antibodies [128]. However, this may largely be due to apoptosis induced by the antibody, and both anti-integrin antibodies and EGFR antagonists cause mammary epithelial cell apoptosis [129,130]. The mechanism of communication between $\beta 1$ integrin and EGFR in breast tumour cells appears indirect, although it has not been fully determined.

Interestingly, the cross-talk only occurs in three-dimensional cultures, and is apparently not related to the loss of tissue organization and altered polarity seen in three-dimensional cultures of breast epithelial cells overexpressing ErbB2 [131]. Since $\beta 1$ integrins have crucial roles in the formation of primary tumours, as well as metastatic dissemination and preventing tumour cell senescence in mouse models of breast and pancreatic cancer (respectively), it will be important to determine whether $\beta 1$ integrin antagonists provide a useful therapeutic approach for human cancer, particularly when used in combination with anti-EGFR strategies [132,133].

Summary

Two of the central signalling modules (i.e. ERK and Akt) ensuring that all of the components for cell-cycle commitment are in place, are co-ordinately regulated by $\beta 1$ integrins and EGFR (as well as other RTKs). Integrins have a further role in cell-cycle regulation through both the Src family kinase and Rac signalling cassettes, and here GFs also contribute to the signalling output [134]. Although not discussed in the present review, integrin–RTK coupling also strongly influences survival and migration, both of which are fates that are linked to spatial and temporal aspects of cell behaviour.

In the bigger picture, integrins and RTKs are no longer seen as individual receptors binding either GFs or ECM proteins, but rather as joint sensing apparatus for cells to detect where they are and how they should respond to instructive signals from other cells (Figure 4). Importantly, the ability of integrins to activate a variety of RTKs indicates that this is a widely used device to enhance the cellular effects of GFs, providing a switch (or turning up the rheostat) that allows GF signalling to be sustained when cells are located within an appropriate ECM (Figure 5a). A consequence is that dysregulation of these systems can have profound effects on the progression of morphogenetic diseases such as cancer.

Major gaps in knowledge

Major gaps in knowledge include: (i) a deep understanding of how the two different receptor systems are spatially configured within the plasma membrane *in vivo* in order to allow physical interactions and signalling cross-talk; (ii) knowledge of the specificities of $\beta 1$ integrin–RTK interactions in different cell types, and two-dimensional compared with three-dimensional compared with *in vivo*; and (iii) elucidation of how their positive interactions are restrained during developmental switches from proliferation to differentiation.

In addition, there are several key questions that still need to be evaluated. (i) A crucial part of integrin function during cell migration is related to endocytic cycling [34]. Since Rab11 controls $\beta 1$ integrin recycling, the same GTPase is also involved

with modulating EGF-induced cell cycle, and Ras/ERK signalling can continue on ‘signalling endosomes’, do early or sorting endosomes have a central role in co-regulation of cell cycle by integrins and RTKs such as EGFR [135,136]? (ii) Some adhesome proteins [e.g. ILK and NEDD9 (neural-precursor-cell-expressed developmentally down-regulated 9)] are found at centrosomes and are involved with mitotic spindle assembly [137,138]. Are integrins or integrin–RTK interactions involved directly with the later stages of mitosis, in addition to the early signalling events? (iii) There are mechanical connections between the ECM and nucleus through integrins, actin/keratin cytoskeletons and the nuclear envelope [139,140]. Do such links directly affect the cell cycle?

SIGNAL INTEGRATION CONNECTING INTEGRINS AND CYTOKINE RECEPTORS

The STAT family of proteins are activated downstream of cytokines to regulate cell-fate responses such as proliferation and differentiation. Cytokine receptors for IL (interleukin), prolactin and IFN (interferon) lack intrinsic kinase activity, and transmit intracellular signals by interacting with protein tyrosine kinases belonging to the JAK (Janus kinase) family [141]. Ligand binding leads to the ligation of two receptor molecules, which brings receptor-associated JAKs in close enough proximity to allow *trans*-phosphorylation and thus activation of the kinase domain. Activated JAKs then phosphorylate the receptors, which provide specific sites for the recruitment of SH2-domain signalling components, including the STATs, and rapid propagation of downstream signals. Tyrosine phosphorylation of STATs by JAK family members leads to nuclear translocation where they bind to specific promoter elements and control expression of target genes. Fine-tuning of this pathway is achieved through regulation by phosphatases including SHP-1, SHP-2 and PTP1B (which exert their effects both positively and negatively), nuclear export of STATs and the SOCS (suppressors of cytokine signalling) proteins [142]. In addition, several of the cytokine receptors and/or JAKs activate other signalling cassettes initiated by Src family kinases and GEFs, e.g. Vav [143], adaptor proteins, such as SH2B1 which can recruit Rac and IRS [144], or adaptor/kinases such as IRAKs (IL-1-receptor-associated kinase), which are involved with innate immune responses [145].

There is a critical dependence on integrins for cytokines to activate intracellular signalling and dictate cell-fate responses in adherent cell types.

Integrins regulate IL-receptor signalling

Signal co-operativity between integrins and IL receptors occurs in a variety of cell systems, with a range of responses.

The epithelial cells lining the intestinal tract are involved in immune responses by producing pro-inflammatory cytokines in response to IL-1 β . Cell–ECM interactions regulate this pathway, because the interaction of Caco-2 cells (IEC) with FN promotes AP-1 (activator protein 1) and NF- κ B activation, and cytokine production, whereas the basement membrane ligand, LM-5 and its cognate receptor $\alpha 3\beta 1$ integrin suppress it [146]. Thus cells in their native environment (i.e. contact with basement membrane) are refractory to IL-1 β , whereas those sensing an altered ECM environment, e.g. following FN exposure in the event of wound healing, might be stimulated to synthesize pro-inflammatory cytokines. The detailed mechanism of how this cross-talk works is not yet known.

The link between IL-3 receptor and $\beta 1$ integrin is better understood, and resembles integrin interactions with some RTKs.

IL-3 acts as a pleiotropic factor in regulating endothelial cell biology, controlling proliferation, migration and survival. In breast cancer for example, IL-3 secretion by infiltrating T-cells promotes angiogenesis. IL-3 drives primary endothelial cell proliferation via the JAK2/STAT5 pathway and c-Fos gene transcription, but integrin-mediated adhesion is a key element in this pathway because: (i) signalling only proceeds when cells are attached to the ECM ligands FN or LM; (ii) activating anti-($\beta 1$ integrin) antibodies trigger IL-3 signalling in the absence of cytokine; and (iii) $\beta 1$ integrin, activated by ECM adhesion or Mn^{2+} , physically associates with the IL-3 β receptor and directly activates JAK2/STAT5 signalling [147]. The two different receptors have separate roles because integrin activation alone stimulates this cytokine pathway only transiently, but addition of IL-3 promotes a much more sustained response and a higher proportion of cells entering the S-phase of the cell cycle (Figure 9a).

Thus, in cells that are naturally adherent, there is an elegant interplay between integrins and cytokine receptors that is required in order for the cytokine to deliver a maximal response. Here, cell adhesion provides a spatial checkpoint to prime the IL-3 signalling axis, which only becomes fully active at times when IL-3 is present.

Integrins regulate the prolactin signalling cascade

A similar situation occurs for prolactin signalling, where cells need to be in contact with the correct ECM environment in order to respond to instructive signals from this endocrine hormone. The mammary gland develops in a temporal and spatially regulated manner such that, during pregnancy, epithelial cells proliferate and then differentiate, but only produce their tissue-specific products (milk) at the right time and place, i.e. during lactation and in epithelial cells within acini [148]. $\beta 1$ integrin adhesion to LM provides the spatial signals controlling this cell-fate process, and prolactin provides the temporal signals [22,149]. Here, both negative and positive influences from the ECM control cytokine signalling.

Prolactin activates the JAK2/STAT5 cascade when mammary cells adhere to LM, but not to collagen I, being inhibited on the latter ECM by a PTP [150], which is likely to be SHP-2 [151]. This PTP can be suppressed chemically or with constitutively activated Rac (V12Rac), restoring prolactin-dependent STAT5 signalling. The mechanism by which V12Rac regulates SHP-2 is unknown, but one possibility is via ROS (reactive oxygen species), which inhibit PTPs.

Active integrin signalling is also essential for driving lactational differentiation, since ablation of $\beta 1$ integrin both *in vivo* and in a primary three-dimensional culture model inhibits the ability of prolactin to activate STAT5 and induce milk protein synthesis [152,153]. Genetic knockout approaches have demonstrated that the adhesion complex protein ILK, via its adaptor function rather than kinase activity, acts downstream of $\beta 1$ integrin to regulate this process [154]. Importantly, not all adhesion complex proteins have equal roles in this aspect of integrin signalling, because although another integrin signalling protein (FAK) is located in the same complex, it does not have a role in mammary differentiation. This suggests that the adhesome circuitry is wired specifically for different cell-fate decisions.

Further on in the pathway (in mammary cells), Rac1 serves as a nodal point integrating signals between integrins and cytokine receptors, since expression of V12Rac in $\beta 1$ integrin-null acini rescues JAK activation and the lactational defect [151]. The link between ILK and Rac is not known, but is presumably an adhesome-recruited GEF. Rac has a further role in JAK/STAT signalling via its effector PAK, which regulates lactational

Figure 9 Integrin connections with cytokine receptors

(a) $\beta 1$ integrins promote IL-3 signalling, but the signal is sustained only in the presence of both ligand and integrin–ECM interactions. (b) $\beta 1$ integrins are required for prolactin signalling, via ILK and Rac1. The link to the prolactin pathway is indirect, and involves intermediates to promote both tyrosine phosphorylation of the receptor and JAK2 activation, as well as full STAT5 activation. S-P, phosphorylated serine; Y-P, phosphorylated tyrosine. (c) Integrins are required for maximal interferon signalling, via cross-talk with PKC.

differentiation in part by phosphorylating STAT5a on Ser⁷⁷⁹ [155]. We view the adhesome complex as a structural framework for localized GEF activation, which in turn activates Rac1 in a spatially restricted manner, leading to transmission of highly localized signals, e.g. prolactin receptor activation in this cell system (Figure 9b). Recent studies have shown that, in the absence of LM, prolactin does trigger its signalling pathway but only transiently and not enough to influence gene expression, whereas the LM–cell interaction enables sufficiently sustained activation of STAT5 for milk protein synthesis [155a]. This means

that LM adhesion acts as a classic rheostat to promote strong prolactin receptor signals, analogous to the integrin–RTK receptor integration (Figure 5b).

Integrins regulate IFN responses

Integrin-mediated adhesion also regulates IFN responses, which in this case is via an indirect mechanism involving PKC ϵ (Figure 9c). In cells responsive to IFN γ , signalling to STAT1 is much stronger in cells that are attached to either FN or the basement-membrane collagen IV than in detached cells or those adhering to fibrillar collagen I [156]. PKC ϵ is also required for the ability of IFN γ to activate STAT1, with the input occurring at a point downstream of JAK1/2. Since integrin-mediated adhesion leads to the phosphorylation and activation of PKC ϵ , it appears that PKC ϵ facilitates the coupling of JAK1/2 to STAT1. It is not clear how integrins directly regulate PKC ϵ activation, but other members of the family, e.g. PKC α , associate with active β 1 integrins, and roles for both members of the PKC family in integrin trafficking have been proposed [157,158]. There may also be a negative regulation of the IFN γ pathway in the absence of appropriate ECM signals, since PP2A phosphatase and PDK1 (phosphoinositide-dependent kinase 1) are recruited to form a complex with PKC ϵ in cells cultured on fibrillar collagen, thereby dephosphorylating and inactivating PKC ϵ and consequently preventing transmission of IFN- γ signals [156].

Adhesion signals relayed by Pyk2 (a homologue of FAK) also contribute to IFN- α and - γ -mediated STAT1 phosphorylation. In this case, the signals may converge at the level of JAK1 by forming a complex, although there is some controversy about the mechanism because in one study Pyk2 binding to JAK1 modulated its phosphorylation status [159], whereas in the other, JAK1 phosphorylation was unaffected [160]. FAK also mediates STAT1 activation upon cell adhesion to FN, but this occurs independently of the JAKs [161].

Although these studies provide tantalizing glimpses of an adhesion checkpoint for IFN signalling, more needs to be learnt about the detailed mechanisms whereby integrins facilitate the pathway, and whether this is a universal mechanism that applies to all cell types.

Summary

A new view of cytokine signalling emerges that, rather than being simple effectors of one-dimensional pathways, as is commonly perceived, in many cell types there is an absolute requirement for integrins in order for cytokines to activate efficient downstream signals. The formation of distinct adhesion signalling platforms, which are likely to be cell type- or ECM-dependent, then influence the intracellular response to hormonal stimulation, as for example in the rheostat model (Figure 5). Identifying the spatial localization of both adhesion and cytokine signalling components in adherent cell types is a major gap in our knowledge, yet fundamental in understanding how they interconnect to regulate various cellular responses. In most of the cases mentioned above, the exact details of the integrin connections with cytokine receptors still need to be worked out.

SIGNAL INTEGRATION BY INTEGRINS AND SYNDECANS

Syndecans are a family of transmembrane proteoglycans that are comprised of a protein core with covalently attached heparan sulfate sugar chains [GAGs (glycosaminoglycans)]. One of their key roles is bind GFs through their GAGs, which trap specific ligands that are either dilute or distant from their specific

Figure 10 Integrin connections with syndecans

(a) Syndecans present GFs to their receptors, and are therefore part of the integrin–GF system. (b) In the initial stages of cell spreading, which is analogous to membrane protrusions at the leading edge of migrating cells, syndecan and integrin collaborate to promote Rac activation and inhibit Rho. S-P, phosphorylated serine; Y-P, phosphorylated tyrosine.

receptors. Cellular responses to FGF-2 are blocked when the syndecan GAGs are disrupted, so they are essential co-receptors for GFs and are therefore a part of the integrin–GF receptor system [162] (Figure 10a).

Syndecans also act as adhesion receptors by engaging with FN, LM or VN [163]. Intracellularly, their short cytoplasmic domain is composed of two conserved regions that bind Src/Fyn and PDZ-domain-containing-proteins respectively, whereas an intervening region is variable and unique to each syndecan. For syndecan-4, the variable region binds both the inositol lipid PtdIns(4,5) P_2 and PKC α , activating the latter in nascent focal adhesions [164]; it also connects to the actin cytoskeleton via α -actinin and enhances focal complex assembly [165].

Taken together, these properties suggest that syndecan behaves in a similar way to integrins. However, it is established that syndecans can co-operate synergistically with integrins to regulate adhesion-complex formation, cell spreading and directional migration. Indeed, there is co-operation between syndecans and VN-binding ($\alpha v \beta 3$, $\alpha v \beta 5$) or LM-binding integrins ($\alpha 2 \beta 1$, $\alpha 6 \beta 4$), and syndecan-4 synergizes with the FN-specific $\alpha 5 \beta 1$ integrin. In addition, syndecans can activate integrins, for example syndecan-1 regulates the migratory function of $\alpha v \beta 3$ integrin [166]. Thus individual combinations of syndecan–integrin pairs influence the type of signalling proteins recruited at adhesion complexes, and consequently the physiological response elicited.

Syndecan-4 collaboration with $\alpha 5 \beta 1$ integrin

As a specific example, syndecan-4 collaboration with $\alpha 5 \beta 1$ integrin jointly influences cell adhesion and directed migration on FN [167]. Here, engagement of $\alpha 5 \beta 1$ integrin to the central-cell binding domain of FN induces the attachment and spreading of fibroblasts [168]. However, focal adhesions only form when the heparin-binding region of FN binds syndecan-4 and activates PKC α . Indeed, syndecan-4-null cells can display impaired adhesions and stress-fibre formation in culture and a delayed wound-healing response (indicating migratory defects) *in vivo*, and moreover PKC α is required for syndecan-induced migration [169,170].

The mechanism for this co-ordinated receptor signalling occurs through a localized activation of Rho family GTPases, which are instrumental in cell spreading and directional migration on ECM substrates, processes requiring both focal adhesion assembly and actin polymerization [8].

Rac1 is transiently activated early in the process of cell spreading on FN, when RhoA is suppressed, and is then followed by Rho activation. This allows protrusions to form at the front of a moving cell, succeeded by retraction at the rear of the cell via stress fibres. However, the initial Rac1 activation does not occur during adhesion via $\alpha 5 \beta 1$ integrin only (i.e. to the 50K fragment of FN), but also requires syndecan-4–ligand interactions (i.e. with the separate heparin-binding domain of FN), and moreover syndecan-4-null fibroblasts are unable to regulate Rac1 activity during spreading on complete FN [171,172]. It seems likely that integrins recruit Rac1 to the plasma membrane at lipid rafts, whereas syndecan-4, via PKC α , localizes the activation of Rac1 to the leading edge of migratory cells [76,172].

At the same time, RhoA is inactivated to prevent stress-fibre formation and to allow the leading edge of cells to move forward, and this is also accomplished by combinatorial signals from $\alpha 5 \beta 1$ integrin and syndecan: here, receptor-derived signals from Src and PKC α (respectively) converge on p190RhoGAP to inactivate Rho [173] (Figure 10b). Subsequently, the maturation of focal complexes into focal adhesions, and stress-fibre formation, becomes dependent on RhoA activation, which also requires co-ordinated activation of $\alpha 5 \beta 1$ integrin and syndecan-4 [174,175].

Together this discrete, and temporally regulated, interplay of ligands, receptors and signalling co-ordinates the complex events of cell migration, and is also important in determining which way a cell will move, i.e. its directional migration.

Summary

Cellular events that were once thought to be largely driven by integrins turn out to be much more complex, although maybe it is not surprising that different receptor systems are needed for processes that are as sophisticated as assembling adhesions and co-ordinating migration. The combinatorial integrin–syndecan engagement with the ECM enables environmental sensing, which activates internal signalling cascades to promote cell phenotype responses. Importantly the adhesion receptors also serve to restrict signalling to specific locations within the cell, and thereby control responses very precisely.

OVERALL CONCLUSIONS

The drivers of cell-fate decisions originate from outside the cell and work in concert to control transcription or other responses. It is now seen that RTK and cytokine receptors, and well as ECM adhesion receptors, do not signal in isolation, but operate in a co-ordinated fashion. Future studies will need to decipher how altering or combining environmental cues has an impact on

signal output, and to identify the exact points of convergence within the signalling networks that control cell function. It also remains to be seen what contribution cell–cell adhesion plays in spatially regulating these signalling processes, and precisely how neighbouring cell types (e.g. stromal cells) can influence non-stromal cell types. Future directions might include the use of proteomics and systems biology to dissect the complexity of such signalling networks, which in turn will yield new therapeutic agents for targeting adhesion-related diseases.

ACKNOWLEDGEMENTS

The authors thank Andrew Gilmore and Mark Morgan for critical reviewing of the manuscript prior to submission.

FUNDING

C. H. S.'s research is supported by the Wellcome Trust [grant number 081203] and Breast Cancer Campaign [grant number 2007NovPR15].

REFERENCES

- Humphries, J. D., Byron, A. and Humphries, M. J. (2006) Integrin ligands at a glance. *J. Cell Sci.* **119**, 3901–3903
- Zaidel-Bar, R., Itzkovitz, S., Ma'ayan, A., Iyengar, R. and Geiger, B. (2007) Functional atlas of the integrin adhesome. *Nat. Cell Biol.* **9**, 858–867
- Lo, S. H. (2006) Focal adhesions: what's new inside. *Dev. Biol.* **294**, 280–291
- Delon, I. and Brown, N. H. (2007) Integrins and the actin cytoskeleton. *Curr. Opin. Cell Biol.* **19**, 43–50
- Larsen, M., Artym, V. V., Green, J. A. and Yamada, K. M. (2006) The matrix reorganized: extracellular matrix remodeling and integrin signaling. *Curr. Opin. Cell Biol.* **18**, 463–471
- Discher, D. E., Janmey, P. and Wang, Y. L. (2005) Tissue cells feel and respond to the stiffness of their substrate. *Science* **310**, 1139–1143
- Tanentzapf, G., Devenport, D., Godt, D. and Brown, N. H. (2007) Integrin-dependent anchoring of a stem-cell niche. *Nat. Cell Biol.* **9**, 1413–1418
- Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T. and Horwitz, A. R. (2003) Cell migration: integrating signals from front to back. *Science* **302**, 1704–1709
- Streuli, C. H. (2009) Integrins and cell-fate determination. *J. Cell Sci.* **122**, 171–177
- Hemler, M. E. (2005) Tetraspanin functions and associated microdomains. *Nat. Rev. Mol. Cell Biol.* **6**, 801–811
- Echarri, A., Muriel, O. and Del Pozo, M. A. (2007) Intracellular trafficking of raft/caveolae domains: insights from integrin signaling. *Semin. Cell Dev. Biol.* **18**, 627–637
- Li, R., Mitra, N., Gratkowski, H., Vilaire, G., Litvinov, R., Nagasami, C., Weisel, J. W., Lear, J. D., DeGrado, W. F. and Bennett, J. S. (2003) Activation of integrin $\alpha 11 \beta 3$ by modulation of transmembrane helix associations. *Science* **300**, 795–798
- Ziegler, W. H., Gingras, A. R., Critchley, D. R. and Emsley, J. (2008) Integrin connections to the cytoskeleton through talin and vinculin. *Biochem. Soc. Trans.* **36**, 235–239
- Salanueva, I. J., Cerezo, A., Guadamillas, M. C. and del Pozo, M. A. (2007) Integrin regulation of caveolin function. *J. Cell Mol. Med.* **11**, 969–980
- Kass, L., Erler, J. T., Dembo, M. and Weaver, V. M. (2007) Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. *Int. J. Biochem. Cell Biol.* **39**, 1987–1994
- Arias-Salgado, E. G., Lizano, S., Sarkar, S., Brugge, J. S., Ginsberg, M. H. and Shattil, S. J. (2003) Src kinase activation by direct interaction with the integrin β cytoplasmic domain. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 13298–13302
- Almeida, E. A., Ilic, D., Han, Q., Hauck, C. R., Jin, F., Kawakatsu, H., Schlaepfer, D. D. and Damsky, C. H. (2000) Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH₂-terminal kinase. *J. Cell Biol.* **149**, 741–754
- Burridge, K. and Wennerberg, K. (2004) Rho and Rac take center stage. *Cell* **116**, 167–179
- Mitra, S. K. and Schlaepfer, D. D. (2006) Integrin-regulated FAK–Src signaling in normal and cancer cells. *Curr. Opin. Cell Biol.* **18**, 516–523
- Legate, K. R., Montanez, E., Kudlacek, O. and Fassler, R. (2006) ILK, PINCH and parvin: the tIPP of integrin signalling. *Nat. Rev. Mol. Cell Biol.* **7**, 20–31
- Giancotti, F. G. and Tarone, G. (2003) Positional control of cell fate through joint integrin/receptor protein kinase signaling. *Annu. Rev. Cell Dev. Biol.* **19**, 173–206
- Katz, E. and Streuli, C. H. (2007) The extracellular matrix as an adhesion checkpoint for mammary epithelial function. *Int. J. Biochem. Cell Biol.* **39**, 715–726

- 23 Green, J. A. and Yamada, K. M. (2007) Three-dimensional microenvironments modulate fibroblast signaling responses. *Adv. Drug Delivery Rev.* **59**, 1293–1298
- 24 Debnath, J. and Brugge, J. S. (2005) Modelling glandular epithelial cancers in three-dimensional cultures. *Nat. Rev. Cancer* **5**, 675–688
- 25 Nelson, C. M. and Bissell, M. J. (2006) Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. *Annu. Rev. Cell Dev. Biol.* **22**, 287–309
- 26 Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. *Cell* **100**, 57–70
- 27 Streuli, C. H. (2006) Cell adhesion and cancer. In *The Molecular Biology of Cancer* (Pelengaris, S. and Kahn, M., eds), pp. 356–387, Blackwell Publishing, Malden, MA, U.S.A.
- 28 Marsh, D., Dickinson, S., Neill, G. W., Marshall, J. F., Hart, I. R. and Thomas, G. J. (2008) $\alpha v \beta 6$ Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. *Cancer Res.* **68**, 3295–3303
- 29 Lu, S., Simin, K., Khan, A. and Mercurio, A. M. (2008) Analysis of integrin $\beta 4$ expression in human breast cancer: association with basal-like tumors and prognostic significance. *Clin. Cancer Res.* **14**, 1050–1058
- 30 Chen, M., Sinha, M., Luxon, B. A., Bresnick, A. R. and O'Connor, K. L. (2009) Integrin $\alpha 6 \beta 4$ controls the expression of genes associated with cell motility, invasion and metastasis including S100A4/metastasin. *J. Biol. Chem.* **284**, 1484–1494
- 31 Collo, G. and Pepper, M. S. (1999) Endothelial cell integrin $\alpha 5 \beta 1$ expression is modulated by cytokines and during migration *in vitro*. *J. Cell Sci.* **112**, 569–578
- 32 Zambruno, G., Marchisio, P. C., Marconi, A., Vascieri, C., Melchiori, A., Giannetti, A. and De Luca, M. (1995) Transforming growth factor- $\beta 1$ modulates $\beta 1$ and $\beta 5$ integrin receptors and induces the *de novo* expression of the $\alpha v \beta 6$ heterodimer in normal human keratinocytes: implications for wound healing. *J. Cell Biol.* **129**, 853–865
- 33 Meighan, C. M. and Schwarzbauer, J. E. (2008) Temporal and spatial regulation of integrins during development. *Curr. Opin. Cell Biol.* **20**, 520–524
- 34 Caswell, P. and Norman, J. (2008) Endocytic transport of integrins during cell migration and invasion. *Trends Cell Biol.* **18**, 257–263
- 35 Muller, D. W. and Bosserhoff, A. K. (2008) Integrin $\beta 3$ expression is regulated by let-7a miRNA in malignant melanoma. *Oncogene* **27**, 6698–6706
- 36 Baldwin, G., Novitskaya, V., Sadej, R., Poche, E., Litynska, A., Hartmann, C., Williams, J., Ashman, L., Eble, J. A. and Berditchevski, F. (2008) Tetraspanin CD151 regulates glycosylation of $\alpha 3 \beta 1$ integrin. *J. Biol. Chem.* **283**, 35445–35454
- 37 Liu, L., He, B., Liu, W. M., Zhou, D., Cox, J. V. and Zhang, X. A. (2007) Tetraspanin CD151 promotes cell migration by regulating integrin trafficking. *J. Biol. Chem.* **282**, 31631–31642
- 38 Yang, X. H., Richardson, A. L., Torres-Arzuay, M. I., Zhou, P., Sharma, C., Kazarov, A. R., Andzelm, M. M., Strominger, J. L., Brown, M. and Hemler, M. E. (2008) CD151 accelerates breast cancer by regulating $\alpha 6$ integrin function, signaling, and molecular organization. *Cancer Res.* **68**, 3204–3213
- 39 Arnaout, M. A., Goodman, S. L. and Xiong, J. P. (2007) Structure and mechanics of integrin-based cell adhesion. *Curr. Opin. Cell Biol.* **19**, 495–507
- 40 Luo, B. H., Carman, C. V. and Springer, T. A. (2007) Structural basis of integrin regulation and signaling. *Annu. Rev. Immunol.* **25**, 619–647
- 41 Kinashi, T. (2005) Intracellular signalling controlling integrin activation in lymphocytes. *Nat. Rev. Immunol.* **5**, 546–559
- 42 Ma, Y. Q., Qin, J. and Plow, E. F. (2007) Platelet integrin $\alpha IIb \beta 3$: activation mechanisms. *J. Thromb. Haemostasis* **5**, 1345–1352
- 43 Wilhelmssen, K., Litjens, S. H. and Sonnenberg, A. (2006) Multiple functions of the integrin $\alpha 6 \beta 4$ in epidermal homeostasis and tumorigenesis. *Mol. Cell. Biol.* **26**, 2877–2886
- 44 Ginsberg, M. H., Partridge, A. and Shattil, S. J. (2005) Integrin regulation. *Curr. Opin. Cell Biol.* **17**, 509–516
- 45 Tabata, T., Kawakatsu, H., Maidji, E., Sakai, T., Sakai, K., Fang-Hoover, J., Aiba, M., Sheppard, D. and Pereira, L. (2008) Induction of an epithelial integrin $\alpha v \beta 6$ in human cytomegalovirus-infected endothelial cells leads to activation of transforming growth factor- $\beta 1$ and increased collagen production. *Am. J. Pathol.* **172**, 1127–1140
- 46 Alam, N., Goel, H. L., Zarif, M. J., Butterfield, J. E., Perkins, H. M., Sansoucy, B. G., Sawyer, T. K. and Languino, L. R. (2007) The integrin-growth factor receptor duet. *J. Cell Physiol.* **213**, 649–653
- 47 Miyamoto, S., Teramoto, H., Gutkind, J. S. and Yamada, K. M. (1996) Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. *J. Cell Biol.* **135**, 1633–1642
- 48 Moro, L., Venturino, M., Bozzo, C., Silengo, L., Altruda, F., Beguinot, L., Tarone, G. and Defilippi, P. (1998) Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. *EMBO J.* **17**, 6622–6632
- 49 Wang, Y. and Chien, S. (2007) Analysis of integrin signaling by fluorescence resonance energy transfer. *Methods Enzymol.* **426**, 177–201
- 50 French-Constant, C. and Colognato, H. (2004) Integrins: versatile integrators of extracellular signals. *Trends Cell Biol.* **14**, 678–686
- 51 Gagnoux-Palacios, L., Dans, M., van't Hof, W., Mariotti, A., Pepe, A., Meneguzzi, G., Resh, M. D. and Giancotti, F. G. (2003) Compartmentalization of integrin $\alpha 6 \beta 4$ signaling in lipid rafts. *J. Cell Biol.* **162**, 1189–1196
- 52 Baron, W., Decker, L., Colognato, H. and French-Constant, C. (2003) Regulation of integrin growth factor interactions in oligodendrocytes by lipid raft microdomains. *Curr. Biol.* **13**, 151–155
- 53 Farrelly, N., Lee, Y. J., Oliver, J., Dive, C. and Streuli, C. H. (1999) Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. *J. Cell Biol.* **144**, 1337–1348
- 54 Lee, Y. J. and Streuli, C. H. (1999) Extracellular matrix selectively modulates the response of mammary epithelial cells to different soluble signaling ligands. *J. Biol. Chem.* **274**, 22401–22408
- 55 Pullan, S. and Streuli, C. H. (1996) The mammary gland epithelial cell. In *Epithelial Cell Culture* (Harris, A., ed.), pp. 97–121, Cambridge University Press, Cambridge, U.K.
- 56 Silva, R., D'Amico, G., Hodivala-Dilke, K. M. and Reynolds, L. E. (2008) Integrins: the keys to unlocking angiogenesis. *Arterioscler. Thromb. Vasc. Biol.* **28**, 1703–1713
- 57 Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L. and Schuh, A. C. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature* **376**, 62–66
- 58 Brekken, R. A., Overholser, J. P., Stastny, V. A., Waltenberger, J., Minna, J. D. and Thorpe, P. E. (2000) Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. *Cancer Res.* **60**, 5117–5124
- 59 Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., Wrasidlo, W. and Chersesh, D. A. (2008) Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 9343–9348
- 60 Kumar, C. C., Malkowski, M., Yin, Z., Tanghetti, E., Yaremko, B., Nechuta, T., Varner, J., Liu, M., Smith, E. M., Neustadt, B. et al. (2001) Inhibition of angiogenesis and tumor growth by SCH221153, a dual $\alpha v \beta 3$ and $\alpha v \beta 5$ integrin receptor antagonist. *Cancer Res.* **61**, 2232–2238
- 61 Soldi, R., Mitola, S., Strasly, M., Defilippi, P., Tarone, G. and Bussolino, F. (1999) Role of $\alpha v \beta 3$ integrin in the activation of vascular endothelial growth factor receptor-2. *EMBO J.* **18**, 882–892
- 62 Mahabeleshwar, G. H., Feng, W., Phillips, D. R. and Byzova, T. V. (2006) Integrin signaling is critical for pathological angiogenesis. *J. Exp. Med.* **203**, 2495–2507
- 63 Mahabeleshwar, G. H., Feng, W., Reddy, K., Plow, E. F. and Byzova, T. V. (2007) Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. *Circ. Res.* **101**, 570–580
- 64 Crisculi, M. L., Nguyen, M. and Eliceiri, B. P. (2005) Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. *Blood* **105**, 1508–1514
- 65 Ishizawa, R. and Parsons, S. J. (2004) c-Src and cooperating partners in human cancer. *Cancer Cell* **6**, 209–214
- 66 Kaneko, Y., Kitazato, K. and Basaki, Y. (2004) Integrin-linked kinase regulates vascular morphogenesis induced by vascular endothelial growth factor. *J. Cell Sci.* **117**, 407–415
- 67 McDonald, P. C., Oloumi, A., Mills, J., Dobrev, I., Maidan, M., Gray, V., Wederell, E. D., Bally, M. B., Foster, L. J. and Dedhar, S. (2008) Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. *Cancer Res.* **68**, 1618–1624
- 68 Hodivala-Dilke, K. (2008) $\alpha v \beta 3$ integrin and angiogenesis: a moody integrin in a changing environment. *Curr. Opin. Cell Biol.* **20**, 514–519
- 69 Weis, S. M., Lindquist, J. N., Barnes, L. A., Lutu-Fuga, K. M., Cui, J., Wood, M. R. and Chersesh, D. A. (2007) Cooperation between VEGF and $\beta 3$ integrin during cardiac vascular development. *Blood* **109**, 1962–1970
- 70 Reynolds, A. R., Reynolds, L. E., Nagel, T. E., Lively, J. C., Robinson, S. D., Hicklin, D. J., Bodary, S. C. and Hodivala-Dilke, K. M. (2004) Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in $\beta 3$ -integrin-deficient mice. *Cancer Res.* **64**, 8643–8650
- 71 Bader, B. L., Rayburn, H., Crowley, D. and Hynes, R. O. (1998) Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins. *Cell* **95**, 507–519
- 72 Francis, S. E., Goh, K. L., Hodivala-Dilke, K., Bader, B. L., Stark, M., Davidson, D. and Hynes, R. O. (2002) Central roles of $\alpha 5 \beta 1$ integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. *Arterioscler. Thromb. Vasc. Biol.* **22**, 927–933
- 73 Soro, S., Orecchia, A., Morbidelli, L., Lacal, P. M., Morea, V., Ballmer-Hofer, K., Ruffini, F., Ziche, M., D'Atri, S., Zambruno, G. et al. (2008) A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through $\alpha 5 \beta 1$ integrin. *Blood* **111**, 3479–3488
- 74 Cascone, I., Napione, L., Maniero, F., Serini, G. and Bussolino, F. (2005) Stable interaction between $\alpha 5 \beta 1$ integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. *J. Cell Biol.* **170**, 993–1004

- 75 Mettouchi, A., Klein, S., Guo, W., Lopez-Lago, M., Lemichez, E., Westwick, J. K. and Giancotti, F. G. (2001) Integrin-specific activation of Rac controls progression through the G₁-phase of the cell cycle. *Mol. Cell* **8**, 115–127
- 76 del Pozo, M. A., Alderson, N. B., Kiosses, W. B., Chiang, H. H., Anderson, R. G. and Schwartz, M. A. (2004) Integrins regulate Rac targeting by internalization of membrane domains. *Science* **303**, 839–842
- 77 Wary, K. K., Mariotti, A., Zurzolo, C. and Giancotti, F. G. (1998) A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. *Cell* **94**, 625–634
- 78 Serini, G., Napione, L., Arese, M. and Bussolino, F. (2008) Besides adhesion: new perspectives of integrin functions in angiogenesis. *Cardiovasc. Res.* **78**, 213–222
- 79 Mitola, S., Brenchio, B., Piccinini, M., Tertoolen, L., Zammataro, L., Breier, G., Rinaudo, M. T., den Hertog, J., Arese, M. and Bussolino, F. (2006) Type I collagen limits VEGFR-2 signaling by a SHP2 protein-tyrosine phosphatase-dependent mechanism. *Circ. Res.* **98**, 45–54
- 80 Margadant, C., Frijns, E., Wilhelmsen, K. and Sonnenberg, A. (2008) Regulation of hemidesmosome disassembly by growth factor receptors. *Curr. Opin. Cell Biol.* **20**, 589–596
- 81 Litjens, S. H., de Pereda, J. M. and Sonnenberg, A. (2006) Current insights into the formation and breakdown of hemidesmosomes. *Trends Cell Biol.* **16**, 376–383
- 82 Murgia, C., Blaikie, P., Kim, N., Dans, M., Petrie, H. T. and Giancotti, F. G. (1998) Cell cycle and adhesion defects in mice carrying a targeted deletion of the integrin $\beta 4$ cytoplasmic domain. *EMBO J.* **17**, 3940–3951
- 83 Pulkkinen, L. and Uitto, J. (1999) Mutation analysis and molecular genetics of epidermolysis bullosa. *Matrix Biol.* **18**, 29–42
- 84 Nikolopoulos, S. N., Blaikie, P., Yoshioka, T., Guo, W., Puri, C., Tacchetti, C. and Giancotti, F. G. (2005) Targeted deletion of the integrin $\beta 4$ signaling domain suppresses laminin-5-dependent nuclear entry of mitogen-activated protein kinases and NF- κ B, causing defects in epidermal growth and migration. *Mol. Cell Biol.* **25**, 6090–6102
- 85 Mercurio, A. M., Rabinovitz, I. and Shaw, L. M. (2001) The $\alpha 6 \beta 4$ integrin and epithelial cell migration. *Curr. Opin. Cell Biol.* **13**, 541–545
- 86 Wilhelmsen, K., Litjens, S. H., Kuikman, I., Margadant, C., van Rheeën, J. and Sonnenberg, A. (2007) Serine phosphorylation of the integrin $\beta 4$ subunit is necessary for epidermal growth factor receptor induced hemidesmosome disruption. *Mol. Biol. Cell* **18**, 3512–3522
- 87 Pankov, R., Endo, Y., Even-Ram, S., Araki, M., Clark, K., Cukierman, E., Matsumoto, K. and Yamada, K. M. (2005) A Rac switch regulates random versus directionally persistent cell migration. *J. Cell Biol.* **170**, 793–802
- 88 Pullar, C. E., Baier, B. S., Kariya, Y., Russell, A. J., Horst, B. A., Marinkovich, M. P. and Isseroff, R. R. (2006) $\beta 4$ integrin and epidermal growth factor coordinately regulate electric field-mediated directional migration via Rac1. *Mol. Biol. Cell* **17**, 4925–4935
- 89 Santoro, M. M., Gaudino, G. and Marchisio, P. C. (2003) The MSP receptor regulates $\alpha 6 \beta 4$ and $\alpha 3 \beta 1$ integrins via 14-3-3 proteins in keratinocyte migration. *Dev. Cell* **5**, 257–271
- 90 Danilkovitch-Miagkova, A., Angeloni, D., Skeel, A., Donley, S., Lerman, M. and Leonard, E. J. (2000) Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src. *J. Biol. Chem.* **275**, 14783–14786
- 91 Giancotti, F. G. (2007) Targeting integrin $\beta 4$ for cancer and anti-angiogenic therapy. *Trends Pharmacol. Sci.* **28**, 506–511
- 92 Lipscomb, E. A. and Mercurio, A. M. (2005) Mobilization and activation of a signaling competent $\alpha 6 \beta 4$ integrin underlies its contribution to carcinoma progression. *Cancer Metastasis Rev.* **24**, 413–423
- 93 Bon, G., Folgiero, V., Di Carlo, S., Sacchi, A. and Falcioni, R. (2007) Involvement of $\alpha 6 \beta 4$ integrin in the mechanisms that regulate breast cancer progression. *Breast Cancer Res.* **9**, 203
- 94 Falcioni, R., Antonini, A., Nistico, P., Di Stefano, S., Crescenzi, M., Natali, P. G. and Sacchi, A. (1997) $\alpha 6 \beta 4$ and $\alpha 6 \beta 1$ integrins associate with ErbB-2 in human carcinoma cell lines. *Exp. Cell Res.* **236**, 76–85
- 95 Folgiero, V., Bachelder, R. E., Bon, G., Sacchi, A., Falcioni, R. and Mercurio, A. M. (2007) The $\alpha 6 \beta 4$ integrin can regulate ErbB-3 expression: implications for $\alpha 6 \beta 4$ signaling and function. *Cancer Res.* **67**, 1645–1652
- 96 Yoon, S. O., Shin, S. and Lipscomb, E. A. (2006) A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the $\alpha 6 \beta 4$ integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. *Cancer Res.* **66**, 2732–2739
- 97 Shaw, L. M. (2001) Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the $\alpha 6 \beta 4$ integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. *Mol. Cell Biol.* **21**, 5082–5093
- 98 Bertotti, A., Comoglio, P. M. and Trusolino, L. (2005) $\beta 4$ integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. *Cancer Res.* **65**, 10674–10679
- 99 Chung, J., Yoon, S. O., Lipscomb, E. A. and Mercurio, A. M. (2004) The Met receptor and $\alpha 6 \beta 4$ integrin can function independently to promote carcinoma invasion. *J. Biol. Chem.* **279**, 32287–32293
- 100 Merdek, K. D., Yang, X., Taglienti, C. A., Shaw, L. M. and Mercurio, A. M. (2007) Intrinsic signaling functions of the $\beta 4$ integrin intracellular domain. *J. Biol. Chem.* **282**, 30322–30330
- 101 Zahir, N., Lakins, J. N., Russell, A., Ming, W., Chatterjee, C., Rozenberg, G. I., Marinkovich, M. P. and Weaver, V. M. (2003) Autocrine laminin-5 ligates $\alpha 6 \beta 4$ integrin and activates RAC and NF- κ B to mediate anchorage-independent survival of mammary tumors. *J. Cell Biol.* **163**, 1397–1407
- 102 Friedland, J. C., Lakins, J. N., Kazanietz, M. G., Chernoff, J., Boettiger, D. and Weaver, V. M. (2007) $\alpha 6 \beta 4$ integrin activates Rac-dependent p21-activated kinase 1 to drive NF- κ B-dependent resistance to apoptosis in 3D mammary acini. *J. Cell Sci.* **120**, 3700–3712
- 103 Bon, G., Folgiero, V., Bossi, G., Felicioni, L., Marchetti, A., Sacchi, A. and Falcioni, R. (2006) Loss of $\beta 4$ integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. *Clin. Cancer Res.* **12**, 3280–3287
- 104 Guo, W., Pylayeva, Y., Pepe, A., Yoshioka, T., Muller, W. J., Inghirami, G. and Giancotti, F. G. (2006) $\beta 4$ integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. *Cell* **126**, 489–502
- 105 Folgiero, V., Avetrani, P., Bon, G., Di Carlo, S. E., Fabi, A., Nistico, C., Vici, P., Melucci, E., Buglioni, S., Perracchio, L. et al. (2008) Induction of ErbB-3 expression by $\alpha 6 \beta 4$ integrin contributes to tamoxifen resistance in ER β 1-negative breast carcinomas. *PLoS ONE* **3**, e1592
- 106 Pu, Q. Q. and Streuli, C. H. (2002) Integrin control of cell cycle: a new role for ubiquitin ligase. *Bioessays* **24**, 17–21
- 107 Aplin, A. E., Stewart, S. A., Assoian, R. K. and Juliano, R. L. (2001) Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. *J. Cell Biol.* **153**, 273–282
- 108 Cabodi, S., Moro, L., Bergatto, E., Boeri Erba, E., Di Stefano, P., Turco, E., Tarone, G. and Defilippi, P. (2004) Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. *Biochem. Soc. Trans.* **32**, 438–442
- 109 Carrano, A. C. and Pagano, M. (2001) Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. *J. Cell Biol.* **153**, 1381–1390
- 110 Renshaw, M. W., Ren, X. D. and Schwartz, M. A. (1997) Growth factor activation of MAP kinase requires cell adhesion. *EMBO J.* **16**, 5592–5599
- 111 Zhu, X., Ohtsubo, M., Bohmer, R. M., Roberts, J. M. and Assoian, R. K. (1996) Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. *J. Cell Biol.* **133**, 391–403
- 112 Jones, S. M. and Kazlauskas, A. (2001) Growth-factor-dependent mitogenesis requires two distinct phases of signalling. *Nat. Cell Biol.* **3**, 165–172
- 113 Moro, L., Dolce, L., Cabodi, S., Bergatto, E., Boeri Erba, E., Smeriglio, M., Turco, E., Retta, S. F., Giuffrida, M. G., Venturino, M. et al. (2002) Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. *J. Biol. Chem.* **277**, 9405–9414
- 114 Bill, H. M., Knudsen, B., Moores, S. L., Muthuswamy, S. K., Rao, V. R., Brugge, J. S. and Miranti, C. K. (2004) Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. *Mol. Cell Biol.* **24**, 8586–8599
- 115 DeMali, K. A., Balciunaite, E. and Kazlauskas, A. (1999) Integrins enhance platelet-derived growth factor (PDGF)-dependent responses by altering the signal relay enzymes that are recruited to the PDGF β receptor. *J. Biol. Chem.* **274**, 19551–19558
- 116 Eminaga, S. and Bennett, A. M. (2008) Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRT6 and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation. *J. Biol. Chem.* **283**, 15328–15338
- 117 Hirsch, E., Barberis, L., Brancaccio, M., Azzolino, O., Xu, D., Kyriakis, J. M., Silengo, L., Giancotti, F. G., Tarone, G., Fassler, R. and Altruda, F. (2002) Defective Rac-mediated proliferation and survival after targeted mutation of the $\beta 1$ integrin cytodomain. *J. Cell Biol.* **157**, 481–492
- 118 del Pozo, M. A., Price, L. S., Alderson, N. B., Ren, X. D. and Schwartz, M. A. (2000) Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. *EMBO J.* **19**, 2008–2014
- 119 Del Pozo, M. A. and Schwartz, M. A. (2007) Rac, membrane heterogeneity, caveolin and regulation of growth by integrins. *Trends Cell Biol.* **17**, 246–250
- 120 Armulik, A., Velling, T. and Johansson, S. (2004) The integrin $\beta 1$ subunit transmembrane domain regulates phosphatidylinositol 3-kinase-dependent tyrosine phosphorylation of Crk-associated substrate. *Mol. Biol. Cell* **15**, 2558–2567
- 121 Velling, T., Nilsson, S., Stefansson, A. and Johansson, S. (2004) $\beta 1$ -Integrins induce phosphorylation of Akt on serine 473 independently of focal adhesion kinase and Src family kinases. *EMBO Rep.* **5**, 901–905

- 122 Velling, T., Stefansson, A. and Johansson, S. (2008) EGFR and $\beta 1$ integrins utilize different signaling pathways to activate Akt. *Exp. Cell Res.* **314**, 309–316
- 123 Mattila, E., Pellinen, T., Nevo, J., Vuoriluoto, K., Arjonen, A. and Ivaska, J. (2005) Negative regulation of EGFR signalling through integrin- $\alpha 1\beta 1$ -mediated activation of protein tyrosine phosphatase TCPTP. *Nat. Cell Biol.* **7**, 78–85
- 124 Tiganis, T., Bennett, A. M., Ravichandran, K. S. and Tonks, N. K. (1998) Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. *Mol. Cell. Biol.* **18**, 1622–1634
- 125 Ursini-Siegel, J., Hardy, W. R., Zuo, D., Lam, S. H., Sanguin-Gendreau, V., Cardiff, R. D., Pawson, T. and Muller, W. J. (2008) ShcA signalling is essential for tumour progression in mouse models of human breast cancer. *EMBO J.* **27**, 910–920
- 126 Briand, P., Nielsen, K. V., Madsen, M. W. and Petersen, O. W. (1996) Trisomy 7p and malignant transformation of human breast epithelial cells following epidermal growth factor withdrawal. *Cancer Res.* **56**, 2039–2044
- 127 Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C. and Bissell, M. J. (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and *in vivo* by integrin blocking antibodies. *J. Cell Biol.* **137**, 231–245
- 128 Wang, F., Hansen, R. K., Radisky, D., Yoneda, T., Barcellos-Hoff, M. H., Petersen, O. W., Turley, E. A. and Bissell, M. J. (2002) Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. *J. Natl. Cancer Inst.* **94**, 1494–1503
- 129 Park, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J. and Bissell, M. J. (2006) $\beta 1$ integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and *in vivo*. *Cancer Res.* **66**, 1526–1535
- 130 Gilmore, A. P., Valentijn, A. J., Wang, P., Ranger, A. M., Bundred, N., O'Hare, M. J., Wakeling, A., Korsmeyer, S. J. and Streuli, C. H. (2002) Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. *J. Biol. Chem.* **277**, 27643–27650
- 131 Muthuswamy, S. K., Li, D., Lelievre, S., Bissell, M. J. and Brugge, J. S. (2001) ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. *Nat. Cell Biol.* **3**, 785–792
- 132 Kren, A., Baeriswyl, V., Lehenbre, F., Wunderlin, C., Strittmatter, K., Antoniadis, H., Fassler, R., Cavallaro, U. and Christofori, G. (2007) Increased tumor cell dissemination and cellular senescence in the absence of $\beta 1$ -integrin function. *EMBO J.* **26**, 2832–2842
- 133 White, D. E., Kurpios, N. A., Zuo, D., Hassell, J. A., Blaess, S., Mueller, U. and Muller, W. J. (2004) Targeted disruption of $\beta 1$ -integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. *Cancer Cell* **6**, 159–170
- 134 Marcoux, N. and Vuori, K. (2003) EGF receptor mediates adhesion-dependent activation of the Rac GTPase: a role for phosphatidylinositol 3-kinase and Vav2. *Oncogene* **22**, 6100–6106
- 135 Palmieri, D., Bouadis, A., Ronchetti, R., Merino, M. J. and Steeg, P. S. (2006) Rab11a differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells. *Breast Cancer Res. Treat.* **100**, 127–137
- 136 von Zastrow, M. and Sorkin, A. (2007) Signaling on the endocytic pathway. *Curr. Opin. Cell Biol.* **19**, 436–445
- 137 Fielding, A. B., Dobrev, I., McDonald, P. C., Foster, L. J. and Dedhar, S. (2008) Integrin-linked kinase localizes to the centrosome and regulates mitotic spindle organization. *J. Cell Biol.* **180**, 681–689
- 138 Pugacheva, E. N. and Golemis, E. A. (2005) The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. *Nat. Cell Biol.* **7**, 937–946
- 139 Ingber, D. E. (2006) Cellular mechanotransduction: putting all the pieces together again. *FASEB J.* **20**, 811–827
- 140 Wilhelmsen, K., Ketema, M., Truong, H. and Sonnenberg, A. (2006) KASH-domain proteins in nuclear migration, anchorage and other processes. *J. Cell Sci.* **119**, 5021–5029
- 141 Schindler, C., Levy, D. E. and Decker, T. (2007) JAK-STAT signaling: from interferons to cytokines. *J. Biol. Chem.* **282**, 20059–20063
- 142 Murray, P. J. (2007) The JAK-STAT signaling pathway: input and output integration. *J. Immunol.* **178**, 2623–2629
- 143 Clevenger, C. V. and Kline, J. B. (2001) Prolactin receptor signal transduction. *Lupus* **10**, 706–718
- 144 Maures, T. J., Kurzer, J. H. and Carter-Su, C. (2007) SH2B1 (SH2-B) and JAK2: a multifunctional adaptor protein and kinase made for each other. *Trends Endocrinol. Metab.* **18**, 38–45
- 145 Gottipati, S., Rao, N. L. and Fung-Leung, W. P. (2008) IRAK1: a critical signaling mediator of innate immunity. *Cell. Signalling* **20**, 269–276
- 146 Stulic, M., Lubin, F. D., O'Donnell, P. M., Tammariello, S. P. and McGee, D. W. (2007) Effect of the $\alpha 3\beta 1$ integrin on the IL-1 stimulated activation of c-Jun N-terminal kinase (JNK) in CACO-2 cells. *Cytokine* **37**, 163–170
- 147 Defilippi, P., Rosso, A., Dentelli, P., Calvi, C., Garbarino, G., Tarone, G., Pegoraro, L. and Brizzi, M. F. (2005) $\beta 1$ Integrin and IL-3R coordinately regulate STAT5 activation and anchorage-dependent proliferation. *J. Cell Biol.* **168**, 1099–1108
- 148 Naylor, M. J. and Streuli, C. H. (2006) Integrin regulation of mammary gland development. In *Integrins and Development* (Danen, E., ed.), pp. 176–185, Landes Bioscience, Georgetown, TX, U.S.A.
- 149 Oakes, S. R., Hilton, H. N. and Ormandy, C. J. (2006) The alveolar switch: coordinating the proliferative cues and cell fate decisions that drive the formation of lobuloalveoli from ductal epithelium. *Breast Cancer Res.* **8**, 207
- 150 Edwards, G. M., Wilford, F. H., Liu, X., Hennighausen, L., Djiane, J. and Streuli, C. H. (1998) Regulation of mammary differentiation by extracellular matrix involves protein-tyrosine phosphatases. *J. Biol. Chem.* **273**, 9495–9500
- 151 Akhtar, N. and Streuli, C. H. (2006) Rac1 links integrin-mediated adhesion to the control of lactational differentiation in mammary epithelia. *J. Cell Biol.* **173**, 781–793
- 152 Li, N., Zhang, Y., Naylor, M. J., Schatzmann, F., Maurer, F., Wintermantel, T., Schuetz, G., Mueller, U., Streuli, C. H. and Hynes, N. E. (2005) $\beta 1$ integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. *EMBO J.* **24**, 1942–1953
- 153 Naylor, M. J., Li, N., Cheung, J., Lowe, E., Lambert, E., Marlow, R., Wang, P., Schatzmann, F., Wintermantel, T., Schuetz, G. et al. (2005) Ablation of $\beta 1$ -integrin in mammary epithelium reveals a key role for integrin in glanular morphogenesis and differentiation. *J. Cell Biol.* **171**, 717–728
- 154 Akhtar, N., Marlow, R., Lambert, E., Schatzmann, F., Lowe, E. T., Cheung, J., Katz, E., Li, W., Wu, C., Dedhar, S. et al. (2009) Molecular dissection of integrin signalling proteins in the control of mammary epithelial development and differentiation. *Development*, doi:10.1242/dev.028423
- 155 Wang, R. A., Vadlamudi, R. K., Bagheri-Yarmand, R., Beuvink, I., Hynes, N. E. and Kumar, R. (2003) Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. *J. Cell Biol.* **161**, 583–592
- 155a Xu, R., Nelson, C. M., Muschler, J. L., Veishe, M., Vonderhaar, B. K. and Bissell, M. J. (2009) Sustained activation of STAT5 is essential for chromatin remodeling and maintenance of mammary-specific function. *J. Cell Biol.* **184**, 57–66
- 156 Ivaska, J., Bosca, L. and Parker, P. J. (2003) PKC ϵ is a permissive link in integrin-dependent IFN- γ signalling that facilitates JAK phosphorylation of STAT1. *Nat. Cell Biol.* **5**, 363–369
- 157 Ng, T., Shima, D., Squire, A., Bastiaens, P. I., Gschmeissner, S., Humphries, M. J. and Parker, P. J. (1999) PKC α regulates $\beta 1$ integrin-dependent cell motility through association and control of integrin traffic. *EMBO J.* **18**, 3909–3923
- 158 Ivaska, J., Whelan, R. D., Watson, R. and Parker, P. J. (2002) PKC ϵ controls the traffic of $\beta 1$ integrins in motile cells. *EMBO J.* **21**, 3608–3619
- 159 Wang, L., Tassoulas, I., Park-Min, K. H., Reid, A. C., Gil-Henn, H., Schlessinger, J., Baron, R., Zhang, J. J. and Ivashkiv, I. B. (2008) 'Tuning' of type I interferon-induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages. *Nat. Immunol.* **9**, 186–193
- 160 Takaoka, A., Tanaka, N., Mitani, Y., Miyazaki, T., Fujii, H., Sato, M., Kovarik, P., Decker, T., Schlessinger, J. and Taniguchi, T. (1999) Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN- γ , but not IFN- α , signaling. *EMBO J.* **18**, 2480–2488
- 161 Xie, B., Zhao, J., Kitagawa, M., Durbin, J., Madri, J. A., Guan, J. L. and Fu, X. Y. (2001) Focal adhesion kinase activates Stat1 in integrin-mediated cell migration and adhesion. *J. Biol. Chem.* **276**, 19512–19523
- 162 Mahalingam, Y., Gallagher, J. T. and Couchman, J. R. (2007) Cellular adhesion responses to the heparin-binding (HepII) domain of fibronectin require heparan sulfate with specific properties. *J. Biol. Chem.* **282**, 3221–3230
- 163 Couchman, J. R. (2003) Syndecans: proteoglycan regulators of cell-surface microdomains? *Nat. Rev. Mol. Cell Biol.* **4**, 926–937
- 164 Koo, B. K., Jung, Y. S., Shin, J., Han, I., Mortier, E., Zimmermann, P., Whiteford, J. R., Couchman, J. R., Oh, E. S. and Lee, W. (2006) Structural basis of syndecan-4 phosphorylation as a molecular switch to regulate signaling. *J. Mol. Biol.* **355**, 651–663
- 165 Greene, D. K., Tumova, S., Couchman, J. R. and Woods, A. (2003) Syndecan-4 associates with α -actinin. *J. Biol. Chem.* **278**, 7617–7623
- 166 Beauvais, D. M., Burbach, B. J. and Rapraeger, A. C. (2004) The syndecan-1 ectodomain regulates $\alpha v\beta 3$ integrin activity in human mammary carcinoma cells. *J. Cell Biol.* **167**, 171–181
- 167 Morgan, M. R., Humphries, M. J. and Bass, M. D. (2007) Synergistic control of cell adhesion by integrins and syndecans. *Nat. Rev. Mol. Cell Biol.* **8**, 957–969

- 168 Bloom, L., Ingham, K. C. and Hynes, R. O. (1999) Fibronectin regulates assembly of actin filaments and focal contacts in cultured cells via the heparin-binding site in repeat III13. *Mol. Biol. Cell.* **10**, 1521–1536
- 169 Echtermeyer, F., Streit, M., Wilcox-Adelman, S., Saoncella, S., Denhez, F., Detmar, M. and Goetinck, P. (2001) Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. *J. Clin. Invest.* **107**, R9–R14
- 170 Mostafavi-Pour, Z., Askari, J. A., Parkinson, S. J., Parker, P. J., Ng, T. T. and Humphries, M. J. (2003) Integrin-specific signaling pathways controlling focal adhesion formation and cell migration. *J. Cell Biol.* **161**, 155–167
- 171 Saoncella, S., Echtermeyer, F., Denhez, F., Nowlen, J. K., Mosher, D. F., Robinson, S. D., Hynes, R. O. and Goetinck, P. F. (1999) Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 2805–2810
- 172 Bass, M. D., Roach, K. A., Morgan, M. R., Mostafavi-Pour, Z., Schoen, T., Muramatsu, T., Mayer, U., Ballestrem, C., Spatz, J. P. and Humphries, M. J. (2007) Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix. *J. Cell Biol.* **177**, 527–538
- 173 Bass, M. D., Morgan, M. R., Roach, K. A., Settleman, J., Goryachev, A. B. and Humphries, M. J. (2008) p190RhoGAP is the convergence point of adhesion signals from $\alpha 5 \beta 1$ integrin and syndecan-4. *J. Cell Biol.* **181**, 1013–1026
- 174 Ren, X. D., Kiosses, W. B. and Schwartz, M. A. (1999) Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. *EMBO J.* **18**, 578–585
- 175 Dovas, A., Yoneda, A. and Couchman, J. R. (2006) PKC β -dependent activation of RhoA by syndecan-4 during focal adhesion formation. *J. Cell Sci.* **119**, 2837–2846

Received 25 September 2008/19 December 2008; accepted 22 December 2008

Published on the Internet 25 February 2009, doi:10.1042/BJ20081948